Trial · NCT01003106

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

NCT01003106, Phase 1, Phase 2, Completed, Peter A Campochiaro, MD; results first posted 2016-03-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions. Trials, record NCT01003106. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01003106

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
NCT number: NCT01003106
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 81 participants, actual
Lead sponsor: Peter A Campochiaro, MD
Conditions: Retinal Vein Occlusion
Interventions: Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
First posted: 2009-10-28
Last updated: 2016-03-15
Results first posted: 2016-03-15

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Incidence and Severity of Ocular and Non-ocular Adverse Events.	36 months
Secondary	Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	Baseline to month 6
Secondary	Mean Change From Month 6 to Month 36 in Best Corrected Visual Acuity in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	Month 6- Month 36
Secondary	Mean Change From Baseline to Month 6 in Central Subfield Thickness in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	Baseline to month 6
Secondary	Mean Change From Month 6 to Month 36 in Central Subfield Thickness in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	Month 6- Month 36

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Incidence and Severity of Ocular and Non-ocular Adverse Events.	36 months	participants	NUMBER
SECONDARY	Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	Baseline to month 6	Letters	MEAN
SECONDARY	Mean Change From Month 6 to Month 36 in Best Corrected Visual Acuity in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	Month 6- Month 36	Letters	MEAN
SECONDARY	Mean Change From Baseline to Month 6 in Central Subfield Thickness in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	Baseline to month 6	microns	MEAN
SECONDARY	Mean Change From Month 6 to Month 36 in Central Subfield Thickness in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	Month 6- Month 36	microns	MEAN

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Incidence and Severity of Ocular and Non-ocular Adverse Events.	BRVO	Patients with Serious Adverse Events	17		participants
Incidence and Severity of Ocular and Non-ocular Adverse Events.	CRVO	Patients with Serious Adverse Events	12		participants
Incidence and Severity of Ocular and Non-ocular Adverse Events.	BRVO	Patient with (non serious) adverse events	37		participants
Incidence and Severity of Ocular and Non-ocular Adverse Events.	CRVO	Patient with (non serious) adverse events	35		participants
Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	BRVO-Ranibizumab 0.5mg Alone		12.1	Standard Error 2.9	Letters
Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	BRVO- Ranibizumab 2.0mg Alone		14.6	Standard Error 2.3	Letters
Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	CRVO- Ranibizumab 0.5mg Alone		15.5	Standard Error 2.4	Letters
Mean Change From Baseline to Month 6 in Best Corrected Visual Acuity in Patients Treated With 0.5mg Versus 2.0mg of Ranibizumab	CRVO- Ranibizumab 2.0mg Alone		15.8	Standard Error 2.4	Letters
Mean Change From Month 6 to Month 36 in Best Corrected Visual Acuity in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	BRVO- Pro re Nata (Prn) Ranibizumab Alone		3.1	Standard Error 3.3	Letters
Mean Change From Month 6 to Month 36 in Best Corrected Visual Acuity in Patients Treated With Prn Ranibizumab+Laser Photocoagulation Versus Prn Ranibizumab Alone.	BRVO- Pro re Nata (Prn) Ranibizumab+Laser Photocoagulation		-2.6	Standard Error 2.2	Letters

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow48

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Baseline to Month 6	STARTED	BRVO- Ranibizumab 0.5mg Alone	22
Baseline to Month 6	STARTED	BRVO- Ranibizumab 2.0mg Alone	20
Baseline to Month 6	STARTED	BRVO- Pro re Nata (Prn) Ranibizumab Alone	0
Baseline to Month 6	STARTED	BRVO- Pro re Nata (Prn) Ranibizumab+Laser Photocoagulation	0
Baseline to Month 6	STARTED	CRVO- Ranibizumab 0.5mg Alone	19
Baseline to Month 6	STARTED	CRVO- Ranibizumab 2.0mg Alone	20
Baseline to Month 6	STARTED	CRVO- Pro re Nata (Prn) Ranibizumab Alone	0
Baseline to Month 6	STARTED	CRVO- Pro re Nata (PRN) Ranibizumab+Laser Photocoagulation	0
Baseline to Month 6	COMPLETED	BRVO- Ranibizumab 0.5mg Alone	22
Baseline to Month 6	COMPLETED	BRVO- Ranibizumab 2.0mg Alone	20

1 to 10 of 48Source ClinicalTrials.gov

See all 48 participant flow

Adverse events94

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Increased IOP	Eye disorders	BRVO	2	42	2
other	Increased IOP	Eye disorders	CRVO	0	39	0
other	Tooth Extraction	General disorders	BRVO	3	42	3
other	Tooth Extraction	General disorders	CRVO	0	39	0
other	Skin Lesion/Skin Rash	Skin and subcutaneous tissue disorders	BRVO	4	42	4
other	Skin Lesion/Skin Rash	Skin and subcutaneous tissue disorders	CRVO	0	39	0
other	Diarrhea	Gastrointestinal disorders	BRVO	2	42	2
other	Diarrhea	Gastrointestinal disorders	CRVO	0	39	0
other	Nausea/Vomiting	Gastrointestinal disorders	BRVO	4	42	4
other	Nausea/Vomiting	Gastrointestinal disorders	CRVO	0	39	0

1 to 10 of 94Source ClinicalTrials.gov

See all 94 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	BRVO
Total, all-cause mortality	CRVO
Total, other adverse events	BRVO	37	42
Total, other adverse events	CRVO	35	39
Total, serious adverse events	BRVO	17	42
Total, serious adverse events	CRVO	12	39

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
BRVO vs CRVO: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01003106

GET https://conductscience.org/api/trials/v1/NCT01003106/flow?page=2

API reference For AI assistants